Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and ...

No company has had a more profound impact on inherited breast and ovarian cancer than Myriad Genetics. Its DNA test to identify women with a sharply increased chance of developing these cancers ...

Myriad Genetics believes the "golden age" of personalized medicine is here. It has captured 90% of the molecular diagnostics market. Yet, the market is still full of potential. Accurate testing ...

SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen ...

One prominent one, sold by the genetic-testing company Myriad Genetics, analyzes a patient's DNA to point a doctor to the best options or doses of drugs like Zoloft and Paxil for an individual ...

Myriad Genetics is a leading molecular diagnostic company that focuses on developing and marketing predictive, personalized, and prognostic medicine tests. The company's financial metrics show ...